Holen Sie sich die Stockscreener-App
14.51
0.14%
-0.04
Schlusskurs vom Vortag:
$14.55
Offen:
$14.54
24-Stunden-Volumen:
110.90K
Relative Volume:
0.14
Marktkapitalisierung:
$5.14B
Einnahmen:
$4.79B
Nettoeinkommen (Verlust:
$-317.00M
KGV:
-15.95
EPS:
-0.91
Netto-Cashflow:
$-59.00M
1W Leistung:
+6.60%
1M Leistung:
+4.53%
6M Leistung:
-11.13%
1J Leistung:
-9.19%
1-Tages-Spanne:
$14.45
$14.65
1-Wochen-Bereich:
$13.61
$14.86
52-Wochen-Spanne:
$10.45
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
14.52 | 5.15B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
480.21 | 172.16B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.85 | 56.16B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
88.54 | 43.38B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
286.39 | 41.71B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
244.07 | 17.70B | 2.96B | 487.70M | 344.00M | 6.68 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Is it time to cut losses on Bausch + Lomb CorporationJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
How to build a custom watchlist for Bausch + Lomb CorporationJuly 2025 Patterns & Community Consensus Trade Alerts - Newser
What machine learning models say about Bausch + Lomb CorporationProduct Launch & Reliable Price Action Trade Plans - Newser
Is now a turning point for Bausch + Lomb CorporationMarket Activity Report & Real-Time Stock Price Movement Reports - Newser
How hedge fund analytics apply to Bausch + Lomb Corporation stockWeekly Volume Report & Daily Price Action Insights - Newser
Stable Stocks to Watch: Hudson Technologies and Bausch + Lomb Underperform, Intuit Shines - AInvest
Eye Care Leader Bausch + Lomb Leadership to Share Strategic Updates at JPM and Morgan Stanley Events - Stock Titan
Bausch + Lomb to Participate in Upcoming Investor Conferences - Yahoo Finance
Bausch + Lomb’s SWOT analysis: ophthalmology leader faces spin-off uncertainty - Investing.com
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know - Yahoo Finance
How Bausch + Lomb Corporation stock performs during market volatilityLow Float Big Mover Alerts - thegnnews.com
TR | OpenAI4o Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $14 - 富途牛牛
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating, Raises Target Price to $13 - 富途牛牛
Analysts' Opinions on Bausch + Lomb Corporation, Avantor, and AptarGroup: A Mixed Bag - AInvest
Bausch + Lomb (NYSE:BLCO) Price Target Raised to $13.00 - Defense World
Is it the right time to buy Bausch + Lomb Corporation stockMaximize gains with proven stock analysis - Jammu Links News
Bausch + Lomb Corporation (NYSE:BLCO) Q2 2025 Earnings Call Transcript - Insider Monkey
Bausch + Lomb Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Bausch & Lomb Raises Price Target to $16.00 Amid Positive Analyst Sentiment. - AInvest
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $16 - 富途牛牛
Bausch + Lomb:HC Wainwright Raises PT to $16, Maintains Buy Rating - AInvest
Bausch & Lomb Corp (BLCO) Q2 2025 Earnings Call Highlights: Navigating Growth Amid Challenges By GuruFocus - Investing.com Canada
Bausch + Lomb Prices Upsizes and Prices a 675-Million Euro Senior Secured Notes Offering - 富途牛牛
Bausch & Lomb Corp SEC 10-Q Report - TradingView
Bausch + Lomb Q2 Adjusted Income Lower, Revenue Increases - 富途牛牛
Earnings call transcript: Bausch + Lomb Q2 2025 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Bausch + Lomb Q2 2025 beats earnings expectations - Investing.com
Bausch + Lomb Lifts Outlook After Beating Revenue Expectations - Finimize
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Bausch + Lomb Announces Second-Quarter 2025 Results - BioSpace
Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates - ca.finance.yahoo.com
Bausch + Lomb: Q2 Earnings Snapshot - San Antonio Express-News
Bausch + Lomb’s (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Bausch + Lomb Q2 2025 slides: Revenue growth accelerates, guidance raised - Investing.com Australia
Bausch + Lomb Q2 2025 slides: Revenue growth accelerates, guidance raised By Investing.com - Investing.com South Africa
Bausch + Lomb tops Q2 expectations, raises full-year guidance By Investing.com - Investing.com Canada
Bausch + Lomb tops Q2 expectations, raises full-year guidance - Investing.com
Bausch + Lomb Q2 2025 Financial Results - TradingView
Examining the Future: Bausch & Lomb's Earnings Outlook - 富途牛牛
Bausch + Lomb Corporation Breaks Below Key Support LevelLow Volatility Stable Growth Picks Rank High - beatles.ru
Stocks In Play: Bausch + Lomb Corporation - Barchart.com
Bausch & Lomb Corp (TSX:BLCO) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops - Stock Titan
Bausch + Lomb Corp expected to post earnings of 7 cents a shareEarnings Preview - TradingView
Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For - Yahoo Finance
What are analysts’ price targets for Bausch + Lomb Corporation in the next 12 monthsIdentify breakout stocks before they peak - Jammu Links News
Bausch + Lomb Maintained at Outperform at RBC Ahead of Q2 Results; Price Target Kept at US$17.00 - 富途牛牛
What analysts say about Bausch + Lomb Corporation stockFree Trend-Following Techniques - Autocar Professional
Earnings Preview: BLCO to Report Financial Results Pre-market on July 30 - 富途牛牛
Bausch & Lomb amends CEO contract and performance stock unit terms By Investing.com - Investing.com South Africa
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.28%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):